Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | RO-3306 | 8.57955379445 | 0.0936 | -0.0084 | 10.6878 | -1.0000 | 5.0000 | 0.9180 | 2.64233079861e-14 |
| MDA-MB-134-VI | AZD2014 | -inf | -0.7122 | ||||||
| MDA-MB-134-VI | AZD5363 | -inf | 0.3909 | ||||||
| MDA-MB-134-VI | AZD6738 | -inf | 0.1117 | ||||||
| HCC1500 | MK 1775 | -inf | -0.9646 | ||||||
| SK-BR-3 | BMS-265246 | -inf | 0.0240 | ||||||
| HCC1419 | LY3023414 | -inf | -0.6005 | ||||||
| CAL-120 | THZ1 | -inf | -0.1577 | ||||||
| SK-BR-3 | AZD6738 | -inf | -0.0818 | ||||||
| HCC70 | THZ1 | -inf | -0.8868 | ||||||
| HCC1395 | AZD6738 | -inf | -0.3125 | ||||||
| MDA-MB-134-VI | BMS-265246 | -inf | 0.0268 | ||||||
| T47D | Ribociclib | -inf | 0.0709 | ||||||
| BT-549 | RO-3306 | -inf | -0.1143 | ||||||
| MDA-MB-134-VI | Ulixertinib | -inf | -0.2948 | ||||||
| MDA-MB-134-VI | Alvocidib | -inf | -0.4621 | ||||||
| HCC1500 | AZD5363 | -inf | 0.9937 | ||||||
| HCC1500 | AZD6738 | -inf | -0.9469 | ||||||
| MCF 10A | Alvocidib | -inf | -0.7589 | ||||||
| HCC1500 | RO-3306 | -inf | -0.9896 | ||||||
| HCC1500 | Senexin B | -inf | -0.9794 | ||||||
| MDA-MB-134-VI | GSK2334470 | -inf | 0.1440 | ||||||
| MDA-MB-134-VI | RO-3306 | -inf | 0.0360 | ||||||
| HCC1500 | Ulixertinib | -inf | 0.3396 | ||||||
| MDA-MB-134-VI | Rucaparib | #NAME? | 0.6274 |